| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 20 |
| 1 | INFLIXIMAB | 16 |
| 2 | VEDOLIZUMAB | 16 |
| 3 | IPILIMUMAB | 12 |
| 4 | NIVOLUMAB | 12 |
| 5 | CEFUROXIME | 11 |
| 6 | FIDAXOMICIN | 11 |
| 7 | PEMBROLIZUMAB | 11 |
| 8 | CHOLESTYRAMINE | 10 |
| 9 | HYDROCORTISONE | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEZLOTOXUMAB | 5 | 0.0143 |
| 1 | FIDAXOMICIN | 11 | 0.0046 |
| 2 | VANCOMYCIN HYDROCHLORIDE | 8 | 0.0010 |
| 3 | CEFUROXIME | 11 | 0.0010 |
| 4 | CHOLESTYRAMINE | 10 | 0.0008 |
| 5 | CEFOXITIN SODIUM | 1 | 0.0007 |
| 6 | TOFACITINIB CITRATE | 9 | 0.0007 |
| 7 | NERANDOMILAST | 1 | 0.0006 |
| 8 | CLINDAMYCIN PHOSPHATE | 2 | 0.0004 |
| 9 | OCTREOTIDE ACETATE | 10 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Macrolide Antibacterial [EPC] | 11 | 0.0109 |
| 1 | Somatostatin Analog [EPC] | 8 | 0.0012 |
| 2 | Bile Acid Sequestrant [EPC] | 10 | 0.0008 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 12 | 0.0002 |
| 4 | Integrin Receptor Antagonist [EPC] | 18 | 0.0002 |
| 5 | Human Immunoglobulin G [EPC] | 3 | 0.0001 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 13 | 0.0001 |
| 7 | Glycopeptide Antibacterial [EPC] | 8 | 0.0001 |
| 8 | Dihydrofolate Reductase Inhibitor Antibacterial [EPC] | 10 | 0.0001 |
| 9 | Anti-anginal [EPC] | 1 | 0.0001 |